Dr Massimo Cristofanilli, MD Joins Datar Cancer Genetics as Strategic Advisor
NEW YORK and LONDON and MUNICH and NEW DELHI, Feb. 11, 2025…
Baylor Genetics Marks a Decade of Leadership in Precision Diagnostics, Empowering Patients, Healthcare Providers and Partners with Trusted Genetic Insights
HOUSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Baylor Genetics, a clinical diagnostic…
Datar Cancer Genetics Unveils Next Generation Multi-Analyte, AI-Powered Decision Support Platform for Personalized Treatment of Difficult-to-Treat Cancers.
LONDON, MUNICH and NEW DELHI, Feb. 3, 2025 /PRNewswire/ -- Datar Cancer Genetics…
Datar Cancer Genetics to Provide Groundbreaking Video-Enhanced Results of In-Vitro Chemotherapy Effectiveness Tests for Cancer Patients
NEW DELHI and LONDON and MUNICH, Jan. 28, 2025 /PRNewswire/ -- Datar…
SOPHiA GENETICS Launches Comprehensive MRD Tracking Capabilities
The cutting-edge OncoPortal™ Mutation Tracker add-on module enables precision monitoring of evolving…
deCODE genetics: Complete recombination map of the human-genome, a major step in genetics
REYKJAVIK, Iceland, Jan. 22, 2025 /PRNewswire/ -- Scientists at deCODE genetics/Amgen have constructed…
Datar Cancer Genetics Introduces Revolutionary Tumor-Agnostic + Informed Blood Test for Residual Disease Monitoring
The Target-MRD blood test uses a combination of tumor-informed and tumor-agnostic molecular…
Datar Cancer Genetics Introduces Revolutionary Tumor-Agnostic + Informed Blood Test for Residual Disease Monitoring
The Target-MRD blood test uses a combination of tumor-informed and tumor-agnostic molecular…
Myriad Genetics RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
SALT LAKE CITY, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc.…
SOPHiA GENETICS Launches MSK-IMPACT powered with SOPHiA DDM at AMP 2024
Launch of new application enables global access to highly recognized solid tumor…